Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | PLAT | P00750 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2526487 | 1.00 | PKM (0.55) | PKMTP53HTTMEN1KMT2A | |
| SCHEMBL503717 | 1.00 | PKM (0.55) | PKMTP53HTTMEN1KMT2A | |
| SCHEMBL1896639 | 0.98 | TP53 (0.57) | PKMTP53HTTMEN1KMT2A | |
| SCHEMBL10141498 | 0.98 | TP53 (0.57) | PKMTP53HTTMEN1KMT2A | |
| SCHEMBL10623074 | 0.98 | PKM (0.54) | PKMTP53HTTMEN1KMT2A | |
| SCHEMBL24919991 | 0.98 | TP53 (0.57) | PKMTP53HTTMEN1KMT2A | |
| SCHEMBL9190483 | 0.98 | TP53 (0.57) | PKMTP53HTTMEN1KMT2A | |
| SCHEMBL9196316 | 0.98 | TP53 (0.57) | PKMTP53HTTMEN1KMT2A | |
| SCHEMBL8435960 | 0.98 | TP53 (0.57) | PKMTP53HTTMEN1KMT2A | |
| SCHEMBL10623080 | 0.98 | PKM (0.54) | PKMTP53HTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| EP-4637728-A1 | COMPOSITION | BioNTech Delivery Technologies GmbH (DE) | 2025-10-29 | — | — | EP | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| WO-2024133635-A1 | COMPOSITION | BIONTECH DELIVERY TECHNOLOGIES GMBH (DE) | 2024-06-27 | — | — | WO | claimed |
| EP-3191088-B1 | AN ANTICONVULSANT COMPOUND | ROYAL HOLLOWAY & BEDFORD NEW COLLEGE (GB) | 2020-12-16 | — | — | EP | claimed |
| US-10301263-B2 | Anticonvulsant compound | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2019-05-28 | — | — | US | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20170305859-A1 | An Anticonvulsant Compound | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2017-10-26 | — | — | US | claimed |
| EP-3191088-A1 | AN ANTICONVULSANT COMPOUND | Royal Holloway And Bedford New College (GB) | 2017-07-19 | — | — | EP | claimed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | claimed |
| WO-2004007709-A2 | PRODUCTION OF POLYKETIDES | BIOTICA TECHNOLOGY LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| WO-2000022909-A2 | SYSTEMS FOR ORAL DELIVERY | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 2000-04-27 | — | — | WO | claimed |
| EP-0363451-B2 | SUPERTWIST LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 1999-12-15 | — | — | EP | claimed |
| EP-0563146-B1 | 2-FLUOROPYRIDINE, PROCESS FOR PRODUCING IT AND ITS USE IN LIQUID CRYSTAL MIXTURES | HOECHST AG (DE) | 1999-10-06 | — | — | EP | claimed |
| EP-0285617-B1 | LIQUID CRYSTAL PHASE | MERCK PATENT GmbH (DE) | 1991-12-27 | — | — | EP | claimed |
| EP-0216672-B1 | MIXTURE OF NEMATIC LIQUID CRYSTALS CONTAINING A 1-(ALKYL CYCLOHEXYL)-2-(ALKYL FLUORO BISPHENYLYL) ETHANE | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1991-01-16 | — | — | EP | claimed |
| EP-0256097-B1 | VINYL COMPOUNDS AND LIQUID CRYSTAL PHASE | MERCK PATENT GmbH (DE) | 1990-08-01 | — | — | EP | claimed |
| EP-0216671-A1 | Mixture of liquid crystals containing a Schiff base | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1987-04-01 | — | — | EP | claimed |
| EP-0216672-A1 | Mixture of nematic liquid crystals containing a 1-(alkyl cyclohexyl)-2-(alkyl fluoro bisphenylyl) ethane | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1987-04-01 | — | — | EP | claimed |
| EP-0033947-B2 | LIQUID CRYSTAL DISPLAY ELEMENT | KABUSHIKI KAISHA TOSHIBA (JP) | 1987-01-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | PKM 2089/4885TP53 234/4885HTT 1387/4885 |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | PKM 2089/4885TP53 234/4885HTT 1387/4885 |
| US-20170305859-A1 | An Anticonvulsant Compound | PSEN2, BACE2, APP | PKM 1500/4885TP53 4790/4885HTT 453/4885 |
| US-10301263-B2 | Anticonvulsant compound | PSEN2, BACE2, APP | PKM 1607/4885TP53 4773/4885HTT 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.